Human Borna disease virus 1 encephalitis shows marked pro-inflammatory biomarker and tissue immunoactivation during the course of disease

Jessica Rauch*\textsuperscript{a}, Johanna Friederike Steffen\textsuperscript{a}, Birgit Muntau\textsuperscript{a}, Jana Gisbrecht\textsuperscript{a}, Kirsten Pörntner\textsuperscript{a}, Christiane Herden \textsuperscript{c}, Hans Helmut Nillerd\textsuperscript{d}, Markus Bausweind\textsuperscript{d}, Dennis Rubbenstroth \textsuperscript{e}, Ute Mehlhoopa, Petra Allartza and Dennis Tappe\textsuperscript{e}

\textsuperscript{a}Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany; \textsuperscript{b}Department of Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany; \textsuperscript{c}Institute for Veterinary Pathology, Justus-Liebig-University Gießen, Gießen, Germany; \textsuperscript{d}Institute of Clinical Microbiology and Hygiene, Regensburg University Hospital, Regensburg, Germany; \textsuperscript{e}Friedrich-Loeffler-Institut, Federal Research Institute for Animal Health, Greifswald-Insel Riems, Germany

ABSTRACT

Human Borna disease virus 1 (BoDV-1) encephalitis is a severe emerging disease with a very high case-fatality rate. While the clinical disease, case definitions, diagnostic algorithms and neuropathology have been described, very little is known about the immunological processes of human BoDV-1 encephalitis. Here, we analyzed serum and cerebrospinal fluid (CSF) samples from 10 patients with fatal BoDV-1 encephalitis for changes of different cytokines, chemokines, growth factors and other biomarkers over time. From one of these individuals, also autopic formalin-fixed brain tissue was analyzed for the expression of inflammatory biomarkers by mRNA levels and immunostaining; in a further patient, only formalin-fixed brain tissue was available and examined in addition. A marked and increasing immune activation from the initial phase to the last phase of acute BoDV-1 encephalitis is shown in serum and CSF, characterized by cytokine concentration changes (IFN\textsuperscript{\textbeta}1, IL-5, IL-6, IL-9, IL-10, IL-12p40, IL-13, IL-18, TGF-\textbeta1) with a predominantly pro-inflammatory pattern over time. IFN\textbeta1 production was demonstrated in endothelial cells, astrocytes and microglia, IL-6 in activated microglia, and TGF-\textbeta1 in endothelial cells, activated astrocytes and microglia. This was paralleled by an increase of chemokines (CCL-2, CCL-5, CXCL-10, IL-8) to attract immune cells to the site of infection, contributing to inflammation and tissue damage. Pathologically low growth factor levels (BDNF, B-NGF, PDGF) were seen. Changed levels of arginase and sTREM further fostered the pro-inflammatory state. This dysbalanced, pro-inflammatory state likely contributes importantly to the fatal outcome of human BoDV-1 encephalitis, and might be a key target for possible treatment attempts.

ARTICLE HISTORY

Received 24 February 2022; Revised 30 June 2022; Accepted 3 July 2022

KEYWORDS

BoDV-1; bornavirus; microglia; astrocyte; cytokine; chemokine

Introduction

Human bornavirus encephalitis is a severe disease caused by two related zoonotic members of the Bornaviridae family, the rarely detected variegated squirrel bornavirus 1 (VSBV-1; species Mammalian 2 orthobornavirus) and the emerging Borna disease virus 1 (BoDV-1; species Mammalian 1 orthobornavirus). While human VSBV-1 infection is so far limited to five confirmed cases in private holdings and zoological gardens, and acquired through contact to exotic squirrels and their secretions [1,2,6,8–10], human BoDV-1 encephalitis cases are increasingly detected and have been described in regions endemic for animal Borna disease (BD) in Germany [6–14]. Besides these sporadic cases, a single solid organ transplantation-related cluster of BoDV-1 encephalitis has also been reported, originating from a donor living in a BoDV-1 endemic region [7]. By now, there are around 40 known human cases in Germany, either published or notified to the Robert Koch Institute [13]. Most of them were diagnosed retrospectively from archived brain tissue material. The geographic presence of BoDV-1 extends to endemic parts of Switzerland, Austria, and Liechtenstein [15,16], and the virus is harboured at least by the bicoloured white-toothed shrew (Crocidura leucodon) as a natural reservoir [15,17].

Human BoDV-1 encephalitis has a very high case-fatality rate [6,18] and its clinical course seems to be more rapid than the course of VSBV-1 encephalitis [1,2,6,8–10]. Clinically, after a short unspecified flu-like prodromal period often with headache and fever, patients show neurological signs including confusion, psychomotor slowing, ataxia or epileptic seizures. The disease rapidly progresses with deterioration in consciousness leading to deep coma.
within days and death after several weeks [8–10,12].

BoDV-1 is non-cytopathogenic, strongly cell-bound and neurotropic in accidental hosts such as humans. Besides neurons, also astrocytes and oligodendrocytes can be infected. For both known zoonotic bornaviruses, a non-purulent panencephalitis can be demonstrated histopathologically, characterized by malacia, perivascular B and T cell cuffing, as well as macrophage accumulation, CD4+ and CD8+ T cell parenchymal infiltration, strong microglial activation, and partly bizarre reactive astrocyte changes [9,11,19]. For human VSBV-1 encephalitis immunopathological mechanisms have already been shown [19]. While the clinical disease [6–14], cranial magnetic resonance imaging findings [7–10,13,20], case definitions and diagnostic algorithms [6,13], as well as the neuropathology [9,11,13,20] have been described for human BoDV-1 encephalitis, very little is known about the immunology and potential immunopathological processes of this infection.

Here we analyzed serum, cerebrospinal fluid (CSF), and formalin-fixed paraffin-embedded (FFPE) brain autopsy samples from patients with fatal BoDV-1 encephalitis for inflammatory biomarker changes in order to shed more light on the immunology and (immune)pathogenesis of the disease. The analyses encompassed flow cytometry-based measurements of cytokine, chemokine, growth factor and other biomarker concentrations from serum and CSF, as well as comparable biomarker mRNA analyses and immunohistology examinations from autopic brain tissue samples.

**Patients, materials and methods**

**Patients and materials**

A total of 11 patients were included in the study, all with acute, severe, and finally fatal BoDV-1 encephalitis acquired in virus-endemic regions of Germany [6,8,12–14] and one recent unpublished case. All cases fulfilled the published case definitions for confirmed BoDV-1 encephalitis [6]. Confirmation was achieved by positive quantitative reverse-transcription polymerase chain reaction (qRT-PCR) results for virus presence from either CSF, brain biopsy, or brain autopsy tissue in the different cases ([6,8,12–14]; in CSF from the unpublished case). From 9 patients, only serum and CSF samples were available. From one patient (patient 3), only FFPE brain autopsy samples could be retrieved. From another patient (patient 11), serum, CSF and FFPE brain autopsy samples were analyzed. Duration of disease from symptom onset until death was 3–8 weeks (Table 1). Sex and age were not disclosed in some patients due to local ethics regulations. Two post solid organ transplant patients were among the individuals included in the study (patient 4 and 5), receiving immunosuppressive treatment. Ethical clearance for this study was obtained from the Medical Board of Hamburg, no. PV5616.

**Measurement of cytokine, chemokine, growth factor and other biomarker concentrations in serum and cerebrospinal fluid**

**Samples and statistics**

Serum and CSF samples were stored at –70°C until biomarker analyses were performed. Biomarker concentrations were analyzed by LEGENDplex (BioLegend, Fell, Germany) from all available sera and CSF at different time points after symptom onset. For analysis, results from sera of BoDV-1 patients were compared to sera of ten healthy uninfected blood donors as controls; results from CSF of BoDV-1 patients were compared to reference values from the literature [21–27]. In addition, to visualize mediator changes over time in an accumulated fashion in our patients with individual long disease courses, the duration of each patient’s illness was split in two equally long periods of time, i.e. two halves. Thus, for example, when a patient had a total disease duration of 4 weeks, the first half comprises the first two weeks of illness, and the second half comprises the last two weeks of illness. The respective sample analysis results were assigned to either of these disease duration halves (“phases”) depending on the sampling date. Statistical interpretation was performed with GraphPad Prism 7 (GraphPad Software Inc., La Jolla, CA). For comparison between two analyzed groups, the Mann–Whitney test was used; for comparison between three or more analyzed groups, the Kruskal–Wallis test with subsequent Dunn’s multiple comparisons test was used. Data of the two immunosuppressed patients (patients 4 and 5) were not included in the statistical analysis.

| Table 1. Characteristics of patients with fatal BoDV-1 encephalitis included in the study. |
|---------------------------------|---------------------------------|---------------------------------|
| Patient number in this study   | Year of symptom onset/Year of diagnosis | Sex/Age | Available patient sample material | Duration of disease (weeks) |
| 1                               | 2019/2019                          | F/11    | S, CSF                          | 4                             |
| 2                               | 2020/2020                          | M/79    | S, CSF                          | 5.5                            |
| 3                               | 2017/2020                          | M/59    | BA                             | 4                              |
| 4                               | 2001/2018                          | Not disclosed* | S, CSF  | 8                              |
| 5                               | 2008/2018                          | Not disclosed* | S, CSF  | 7                              |
| 6                               | 2016/2018                          | Not disclosed* | S, CSF  | 4                              |
| 7                               | 2017/2018                          | Not disclosed* | S, CSF  | 7                              |
| 8                               | 2019/2019                          | F/55    | T, S                           | 3                              |
| 9                               | 2020/2020                          | Not disclosed*/71 | S, CSF  | 4                              |
| 10                              | 2020/2021                          | M/65    | S, CSF, BA                      | 6.5                            |
| 11                              | 2021/2021                          | M/79    | S, CSF, BA                      | 6.5                            |

Abbreviations: S, serum; CSF, cerebrospinal fluid; BA, formalin-fixed brain autopsy material.

*According to local ethics committee regulations.
Mediator detection limits
The standard detection limits of the LEGENDplex assay for the analyzed biomarkers were as follows in alphabetical order: arginase (3.01 pg/mL), basic fibroblast growth factor (FGFβ, 40.3 pg/mL), beta-nerve growth factor (β-NGF, 0.5 pg/mL), brain-derived neuromotrophic factor (BDNF, 5.9 pg/mL), CC-chemokine ligand 2 (CCL-2, N/A), CCL-3 (4.1 pg/mL), CCL-4 (4.2 pg/mL), CCL-5 (83.3 pg/mL), CCL-17 (1.8 pg/mL), chemokine (C-X3-C motif) ligand 1 (CCL5, N/A), C-X-C motif chemokine 10 (CXCL10, N/A), granulocyte colony-stimulating factor (G-CSF, 23.6 pg/mL), granulocyte-macrophage colony-stimulating factor (GM-CSF, 22.7 pg/mL), interferon-α (IFNα, 19.5 pg/mL), interferon-γ (IFNγ, 5.1 pg/mL), interleukin (IL) 1β (5.3 pg/mL), IL-2 (3.2 pg/mL), IL-5 (4.5 pg/mL), IL-5 (4.0 pg/mL), IL-6 (5.2 pg/mL), IL-8 (N/A), IL-9 (4.9 pg/mL), IL-10 (3.9 pg/mL), IL-12p40 (0.9 pg/mL), IL-12p70 (19.5 pg/mL), IL-13 (5.1 pg/mL), IL-17A (5.0 pg/mL), IL-17F (3.7 pg/mL), IL-18 (2.0 pg/mL), IL-21 (3.9 pg/mL), IL-22 (2.0 pg/mL), IL-23 (1.2 pg/mL), platelet-derived growth factor BB (PDGF-BB, 29.6 pg/mL), soluble receptor for advanced glycation end products (sRAGE, 15.5 pg/mL), soluble triggering receptor expressed on myeloid cells 1 (sTREM-1, 12.7 pg/mL), sTREM-2 (N/A), transforming growth factor beta 1 (TGF-β1, 3.1 pg/mL), tumour necrosis factor (TNF, 5.1 pg/mL), and vascular endothelial growth factor (VEGF, 31.4 pg/mL).

Molecular detection of cytokine, chemokine and other biomarker mRNA in FFPE brain tissue samples

Tissues, RNA extraction and PCRs
RNA from several brain regions (frontal, temporal, parietal and occipital cortex; hippocampus, basal ganglia, thalamus, pons, cerebellum) was extracted as described elsewhere [28] using the RNeasy FFPE Kit (Qiagen, Hilden, Germany). RNA yield was measured using the Qubit RNA HS Assay Kit (Invitrogen-Thermo Fisher Scientific, Waltham, MA, USA) following the manufacturer’s instructions. RNA quality was checked regarding purity (260/280 nm) and contamination (260/230 nm) using a NanoDrop 2000c spectrophotometer (Thermo Fisher Scientific). To ensure RNA quality, DNase digestion was performed as part of the RNA purification using the RNeasy FFPE Kit. Additionally, patient samples were tested in reference gene qPCR (see below) before proceeding with further analysis. In case the reference gene could not be detected, samples were excluded. Pooled RNA from the brains of five donors (BioChain, Newark, CA, USA) was used as a reference sample. Reverse transcription was performed using the High-Capacity cDNA Reverse Transcription Kit or the High Capacity RNA-to-cDNA-Kit (both from Applied Biosystems-Thermo Fisher Scientific). All biomarker qPCRs were performed with technical duplicates, using the Taqman Fast Advanced MasterMix (Applied Biosystems-Thermo Fisher Scientific). Due to the very limited amount of patient samples, the use of 3 or more technical replicates was unfortunately not possible. Efficiencies for qPCR assays were analyzed by testing the qPCR of each gene using a dilution series of the control sample (at least 3 dilution steps). Efficiency calculation was performed using the LightCycler 480 software (Release 1.5.1.62; Roche, Basel, Switzerland) and included in the respective relative gene expression analysis (efficiencies of 1.963–2.296; ideal value: 2.0).

qPCR for BoDV-1 was performed as described elsewhere [7,8]. BoDV-1 copy numbers were calculated by using the standard curve of the titrated synthetic positive control oligonucleotide with known molarity and copy number. RNA concentration was measured by Qubit and the viral copy number was calculated per ng sample RNA.

Biomarker gene analyses

cDNAs were analyzed for relative gene expression of human arginase 1 (ARG1), fibroblast growth factor (FGF1), glial fibrillary acidic protein (GFAP), IFNG, IL1RN, IL4, IL9, IL10, IL12B, IL23A, lipocardin 2 (LCN2), mannose receptor C-type 1 (MRC1), inducible nitric oxide synthase 2 (NOS2), resistin-like beta (RETNLB), and TGFB1 by TaqMan Assays (Applied Biosystems). Expression of genes for C1q (C1QA), C3, CCL2, CCL5, CXCL8, CXCL10, frizzled class receptor 1 (FZD1), insulin-like growth factor 1 (IGF1), IL1A, IL1B, IL6, IL13, tissue metallopeptidase inhibitor 1 (TIMP1), TNF and triggering receptor expressed on myeloid cells 2 (TREM2) was analyzed using self-designed primers and probes supplied by Biomers.net GmbH (Ulm, Germany; Online Appendix Table 1). Relative gene expression of biomarker mRNA was analyzed with an efficiency-corrected model for one sample [29], based on the delta-ct of the patient sample in correlation to the delta-ct of the healthy control.

Reference gene selection
For the potential references genes (ACTB, EEF2, GAPDH, NDUGB1, NDUFB4, PEA15 and PPA1), primers and probes were also self-designed (Biomers.net; Online Appendix Table 1). NDUFB4 and NDUFB1 are known to best meet published selection criteria for reference gene expression studies of human brain tissue [30]. Additionally, ACTB, EEF2, GAPDH, as well as PEA15 and EEF2 were selected from the online database for housekeeping genes and reference gene candidates (housekeeping.unicamp.br). Reference gene validation was performed using human astrocyte, microglia and microvascular brain
endothelial cell lines (Applied Biological Materials, Richmond, Canada) kept in RPMI medium (PAN-Biotec, Aidenbach, Germany) and sampled at a minimum of four time points. Therefore, RNA was isolated using the RNeasy Kit (Qiagen), and reverse transcription was performed as described above. Genes were analyzed for their expression stability over time within each cell line as well as between the cell lines using NormFinder [31]. The reference gene should have the lowest possible intragroup variation (variation within samples of the same origin taken at different time points) as well as intergroup variation (variation within samples of different origin).

**Immunohistology of biomarkers**

Available FFPE brain tissue samples were processed for routine histology with haematoxylin and eosin stains. Immunohistology was performed for biomarkers that were found to be detectable by the preceding molecular analysis (see legend of Figure 4). After pretreatment with buffers containing EDTA (pH 9) or citrate (pH 5 or 6) and endogenous peroxidase blocking, the FFPE tissue sections were incubated with the respective antibodies in 1% bovine serum albumin (BSA; Sigma-Aldrich/Merck, Taufkirchen, Germany) at room temperature overnight. This step was followed by incubation with the DCS-AEC 2 Component Detection Kit and 3-aminopyrene substrate (DCS-diagnostics, Hamburg, Germany) for immunoperoxidase staining, and the DCS AP Detection Kit and new fuchsin substrate (DCS-diagnostics, Hamburg, Germany) at room temperature overnight. This step was followed by incubation with the DCS-AEC 2 Component Detection Kit and 3-aminopyrene substrate (DCS-diagnostics, Hamburg, Germany) for immunoperoxidase staining, and the DCS AP Detection Kit and new fuchsin substrate (DCS-diagnostics) for immunoperoxidase staining. As negative control, the respective primary antibody was omitted.

**Results**

**Cytokine, chemokine, growth factor and other biomarker concentrations in serum and cerebrospinal fluid**

**Differences of median biomarker levels between BoDV-1 encephalitis patients and controls**

In serum, levels of the cytokines IL-6 and TFG-β1 were either similar between patients and controls or decreased. Decreases of TGF-β1 were detected from the first to the second phase of illness. For TGF-β1, concentrations were higher in both phases than in controls (Figure 2(A), Table 2). In serum, decreases of the chemokines CCL-2, CCL-5, CXCL-10 and IL-8 were below the detection limit in both groups (Figure 1(B), Table 2). In serum, levels of CCL-2, CCL-10 and IL-8 demonstrated a striking increase in BoDV-1 patients; this increase was less for CCL-3 (Figure 1(B), Table 3). No CSF reference values could be found for CCL-5 and CCL-17 in the literature.

In serum, levels of the growth factors BDNF, β-NGF, PDGF-BB and VEGF were noted in BoDV-1 patients when compared to controls (Figure 1(C), Table 2). In CSF, levels of BDNF, β-NGF and PDGF-BB were below the detection limit in BoDV-1 patients. In contrast, VEGF levels demonstrated a prominent increase (Figure 1(C), Table 3). No CSF reference values could be found for β-NGF and PDGF-BB in the literature.

In serum, concentrations of the other biomarkers arginase and stREM2 were elevated in BoDV-1 patients, while the levels of sRAGE were decreased. Levels of G-CSF and stREM-1 were below the detection limits in patients and controls (Figure 1(D), Table 2). In CSF, arginase concentrations were below the detection limits in BoDV-1 patients, while stREM-2 levels were slightly increased, and stREM-1 levels showed a marked decrease (Figure 1(D), Table 3). No CSF reference values could be retrieved for G-CSF and sRAGE in the literature.

In the two immunosuppressed patients, no specific common pattern could be discerned; in patient 5 however, many cytokines and chemokines showed high concentrations.

Serum and CSF concentrations of FGFb, CCL-4, CXCL1, GM-CSF, IFNα, IL-1β, IL-2, IL-4, IL-12p70, IL-17A, IL-17F, IL-21, IL-22, IL-23 and TNF were either similar between patients and controls or below the detection limits (data not shown).

**Changes of median biomarker levels during different phases of BoDV-1 encephalitis**

When different phases were analyzed, serum concentrations of the cytokines IFNγ, IL-9 and IL-10 were below the detection limit in BoDV-1 patients, while levels of IL-5, IL-6, IL-12p40, IL-13 and IL-18 increased from the first to the second phase of the disease. Decrease of TGF-β1 levels were detected from the first to the second phase of illness. For TGF-β1, concentrations were higher in both phases than in controls (Figure 2(A), Table 2). In serum, concentrations of IFNγ, IL-5, IL-6, IL-10, IL-12p40, IL-18 and TGF-β1 showed an increase from the first phase of illness to the second phase. Levels of IFNγ and IL-6 exceeded the reference values from the literature in both analyzed phases by far. In contrast, levels of IL-
9 and IL-13 decreased from the first phase of the disease to the second (Figure 2(A), Table 3).

In serum, levels of the chemokines CCL-2, CXCL-10 and IL-8 were increased in BoDV-1 patients in the first phase of the disease compared to controls, reaching maximum concentrations in the second phase. CCL-5 and CCL-17 expressions were similar in the first phase of illness and the control group; CCL-5 increased and CCL-17 decreased in the second phase of illness. CCL-3 levels were below the detection limit in either

Figure 1. Cytokine, chemokine, growth factor and other biomarker changes in serum and cerebrospinal fluid of patients with BoDV-1 encephalitis. Serum (black) and CSF (grey) samples from ten BoDV-1 encephalitis patients and serum samples from ten healthy controls (hc) were analyzed in parallel for cytokines (panel A), chemokines (panel B), growth factors (panel C) and other biomarkers (panel D) by bead-based LEGENDplex assay. Results of two immunosuppressed patients are highlighted, patient 4 in red and patient 5 in blue. See Table 2 for median measurements of patient biomarkers and healthy controls in serum (including p values and confidence intervals) and Table 3 for median measurements of patient biomarkers (including confidence intervals) and reference values of biomarkers in CSF. Data are shown as median with interquartile range. β-NGF, beta-nerve growth factor; BDNF, brain-derived neurotrophic factor; CCL, CC-chemokine ligand; CXCL, C-X-C motif chemokine; G-CSF, granulocyte colony-stimulating factor; IFN, interferon; IL, interleukin; PDGF-BB, platelet-derived growth factor BB; sRAGE, soluble receptor for advanced glycation end products; sTREM, soluble triggering receptor expressed on myeloid cells; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; VILIP, visinin-like protein.
The two immunosuppressed patients were not included in the statistical analysis.

Statistically significant differences were found between the phases and the control, as indicated by the asterisks. No significant differences were detected between the two phases of illness.

Asterisks indicate statistically significant differences (*<0.05, **<0.01, ***<0.001, ****<0.0001). Significant changes are shown in bold face. The two immuno-suppressed patients were not included in the statistical analysis.

The results as above in the comparison of BoDV-1 patients and healthy controls.

### Table 2. Concentrations of cytokines, chemokines, growth factors and other biomarkers in sera of BoDV-1 encephalitis patients and healthy controls.

| Biomarker | Median concentration in sera of BoDV-1 encephalitis patients (pg/mL) | Median concentration in sera of controls (pg/mL) |
|-----------|-------------------------------------------------|-------------------------------------------------|
| **Cytokines** | **Total** | **First phase of illness** | **Second phase of illness** | **Total** | **First phase of illness** | **Second phase of illness** |
| IFN-γ | BDL (BDL) | BDL (BDL) | BDL (BDL-17.6) | BDL (BDL) |
| IL-5 | BDL (BDL-11.1) | BDL (BDL) | 6.6 (BDL-27.5) | 5.3 (BDL-7.1) |
| IL-6 | 12.2* [BDL-163.8] | BDL (BDL) | 102.1* [BDL-333.5] | BDL (BDL-5.8) |
| IL-9 | BDL (BDL-9.3) | BDL (BDL) | BDL (BDL-33.4) | 5.6 (BDL-8.5) |
| IL-10 | BDL (BDL-12.2) | BDL (BDL) | BDL (BDL-17.6) | BDL (BDL) |
| IL-12p40 | 1.8 (BDL-4.5) | 1.1 (1.1–11) | 1.9 (BDL-31.6) | 1.8 (1.1–2.8) |
| IL-13 | 21.0* [BDL-29.1] | 13.0 (BDL-30.1) | BDL (BDL-127.2) | 37.4 (52.2–50.7) |
| IL-18 | 104.4 [424–219.1] | 45.3 [37.5–53.0] | 132.0 [36.6–348.3] | 157.6 [73.4–288.8] |
| TGF-β1 | 44.1 [7.9–287.2] | 127.2 [7.9–246.6] | 55.4 [6.5–1941.0] | 13.9 [BDL-283.5] |
| **Chemokines** | | | |
| CCL-2 | 460.0 [189.4–1327.0] | 331.7 [292.9–370.5] | 543.8 [166.6–3911.0] | 243.2 [171.2–368.8] |
| CCL-3 | BDL (BDL-6.0) | BDL (BDL-5.9) | BDL (BDL-17.5) | BDL (BDL) |
| CCL-5 | 35030.0 [795.7–7141.0] | 1843.0 [795.7–2890.0] | 4689.0* [823.9–12014.0] | 2054.0 [1190.0–2218.0] |
| CCL-17 | 25.2 [4.0–164.2] | 78.4 [4.0–152.8] | 22.5 [BDL-392.2] | 81.0 [56.8–137.1] |
| CXCL-10 | 56.6 [11.2–250.1] | 24.6 [13.1–40.0] | 126.0* [112.4–1836.0] | 20.0 [8.5–42.2] |
| IL-8 | 44.9*** [17.0–240.9] | 18.1 [13.3–22.9] | 112.7** [26.5–333.0] | 9.5 [6.0–23.3] |
| **Growth Factors** | | | |
| BDNF | 3935.0*** [1452.0–6574.0] | 3861.0 [1669.0–6053.0] | 3452.0** [374.3–8535.0] | 12382.0 [7722.0–15217.0] |
| β-NGF | BDL** (BDL-1.0) | BDL (BDL-0.5) | 0.5 (BDL-3.0) | 1.6 (0.5–5.7) |
| PDGF-BB | 9179.0** [5140.0–40046.0] | 19860.0 [6177.0–33595.0] | 11177.0 [2075.0–84380.0] | 42191.0 [32664.0–97819.0] |
| VEGF | 1128.0 [91.8–143.5] | 94.9 [94.8–95.0] | 124.4 [93.8–225.2] | 127.6 [116.1–141.4] |
| **Others** | | | |
| Arginase | 1200.0* [417.9–6070.0] | 395.5 [223.1–567.9] | 4970.0* [429.3–23248.0] | 2744.0 [1383.4–456.2] |
| G-CSF | BDL (BDL-52.7) | BDL (BDL) | BDL (BDL-140.4) | BDL (BDL-140.8) |
| sTREM-1 | BDL (BDL-21.1) | BDL (BDL) | BDL (BDL-509.1) | 39.5 [BDL-75.3] |
| sTREM-2 | 3199.0** [2325.0–7178.0] | 4297.0 [2328.0–6267.0] | 3570.0* [2207.0–7627.0] | 1524.0 [9307.0–2705.0] |

BDL = below detection limit.
CI = confidence interval.

Sera of BoDV-1 patients (Total) were compared to healthy serum controls; Statistical analyses were performed with Mann-Whitney test.

Sera of BoDV-1 patients from the two phases were compared with each other and the healthy serum control; Statistical analyses were performed with Kruskal-Wallis test and subsequent Dunn’s multiple comparisons test.

Statistically significant differences were found between the phases and the control, as indicated by the asterisks. No significant differences were detected between the two phases of illness.

Asterisks indicate statistically significant differences (*<0.05, **<0.01, ***<0.001, ****<0.0001). Significant changes are shown in bold face. The two immuno-suppressed patients were not included in the statistical analysis.

In serum, concentrations of the growth factors BDNF, β-NGF, PDGF-BB and VEGF in BoDV-1 patients were decreased in both phases of the disease in comparison to controls (Figure 2(C), Table 2). In CSF, levels of BDNF, β-NGF and PDGF-BB were below the detection limit in either phase of illness, whereas VEGF concentrations were elevated in both phases (Figure 2(C), Table 3).

In serum, the other biomarkers arginase and sTREM-1 showed increasing levels in BoDV-1 patients from the first to the second phase of illness, while sTREM-2 decreased. Concentrations of G-CSF and sRAGE were below the detection limit in either phase (Figure 2(D), Table 2). In CSF, arginase levels were only detectable in the first phase, and sRAGE in neither phase. G-CSF, sTREM-1 and sTREM-2 increased during the second phase. Levels of sTREM-2 reached concentrations above the reference value from the literature (Figure 2(D), Table 3).

From the two immuno-suppressed patients samples were available for phase one only, showing similar results as above in the comparison of BoDV-1 patients with healthy controls.

Serum and CSF concentrations of FGFb, CCL-4, CX3CL1, GM-CSF, IFNα, IL-1β, IL-2, IL-4, IL-12p70, IL-17A, IL-17F, IL-21, IL-22, IL-23 and TNF were either similar between patients and controls or below the detection limits (data not shown).

**Molecular detection of cytokine, chemokine and other biomarker mRNA in FFPE brain tissue samples**

Of the two cases from whom autopsy FFPE material was available, RNA of sufficient quantity and quality could be extracted from three samples of each
patient. The samples included hippocampus, basal ganglia and thalamus of patient 3, and hippocampus, basal ganglia and the occipital lobe of patient 11. Using NormFinder, NDUFB4 could be identified as the overall strongest increase in gene expression. Less was detected. In comparison to hippocampus and basal ganglia, a decreased FGF1 expression and TIMP1 showed a slight increase, whereas, except for the basal ganglia, a decreased FGFI expression was detected. In comparison to hippocampus and thalamus, the basal ganglia of patient 3 demonstrated the overall strongest increase in gene expression. Less positive results could be obtained from RNA of patient 11. Nevertheless, the increased GFAP expression, as well as the decreased FGFI expression of patient 11, correlated with data from patient 3.

BoDV-1 copy numbers ranged from 113,387–256,604/ng RNA with higher viral loads in patient 3 than in patient 11. Highest viral copy numbers were found in the thalamus of patient 3 (Figure 3).

**Immunohistology of biomarkers in FFPE brain tissue samples**

Immunostaining for biomarkers in brain tissue areas found to show detectable results in the molecular detection assays of the two patients was positive for various cell types (Figure 4). Staining for GFAP showed activated astrocytes throughout (Figure 4(A)), whereas staining for IFNγ was positive primarily around blood vessels, indicating production in endothelial cells, and most likely in perivascular microglia and astrocytes (Figure 4(B)). Staining for IL-6 was positive in activated microglia (Figure 4(C)), while FGF was detected in perivascular brain cells, oligodendrocytes and weakly in enlarged astrocytes (Figure 4(D)). TGF-β could be demonstrated in endothelial cells,

**Table 3. Concentrations of cytokines, chemokines, growth factors and other biomarkers in CSF of BoDV-1 encephalitis patients and of controls from the literature.**

| Biomarker       | Median concentration in CSF of BoDV-1 encephalitis patients (pg/mL) [95% CI] | Concentration in CSF of controls (pg/mL), (literature reference) |
|-----------------|--------------------------------------------------------------------------------|---------------------------------------------------------------|
| **Cytokines**   |                                                                                   |                                                              |
| IFNγ            | 41.5 [15.7–153.5]                                                                | 20.8 [BDL–41.5]                                               |
| IL-5            | BDL [BDL–34.3]                                                                   | 8.3 [BDL–98.8]                                               |
| IL-6            | 88.5 [11.7–810.2]                                                                | 22.0 [BDL–41.4]                                               |
| IL-9            | 6.5 [BDL–43.0]                                                                    | 188.4 [120–364.9]                                            |
| IL-10           | 4.5 [BDL–10.3]                                                                    | BDL [BDL–41]                                                |
| IL-12p40        | 4.2 [1.2–15.1]                                                                     | BDL [BDL–1.2]                                               |
| IL-13           | BDL [BDL–44.5]                                                                    | BDL [BDL–44.5]                                             |
| IL-18           | 6.4 [BDL–100.0]                                                                   | BDL [BDL–100]                                              |
| TGF-β1          | 9.9 [3.3–13.3]                                                                     | 6.8 [BDL–13.5]                                              |
| **Chemokines**  |                                                                                   |                                                              |
| CCL-2           | 125.8                                                                             | 1223.0 [477.4–1968.0]                                        |
| CCL-3           | 5.3 [BDL–17.6]                                                                    | BDL [BDL–5.3]                                              |
| CCL-5           | BDL [BDL]                                                                         | BDL [BDL–270.2]                                             |
| CCL-17          | 69.9 [3.6–224.8]                                                                   | BDL [BDL–21.3]                                             |
| CXCL-10         | 9631.0 [7225.0–22004.0]                                                           | 2753.0 [290.3–5216.0]                                       |
| IL-8            | 5211.7 [77.3–1314.0]                                                              | 396.0 [77.3–714.8]                                          |
| **Growth Factors** |                                                                                   |                                                              |
| BDNF            | BDL [BDL–10.6]                                                                    | BDL [BDL–10.6]                                             |
| β-NGF           | BDL [BDL–0.5]                                                                      | BDL [BDL–0.5]                                              |
| PDGF-BB         | BDL [BDL]                                                                         | BDL [BDL]                                                  |
| VEGF            | 78.1 [50.9–134.2]                                                                   | 48.7 [BDL–97.3]                                             |
| **Others**      |                                                                                   |                                                              |
| Arginase        | BDL [BDL–117.0]                                                                    | 58.5 [BDL–117.0]                                           |
| G-CSF           | BDL [BDL–318.0]                                                                   | 31.4 [BDL–62.8]                                           |
| sRAGE           | BDL [BDL]                                                                         | BDL [BDL]                                                  |
| sTREM-1         | 13.7 [BDL–96.8]                                                                    | BDL [BDL–96.8]                                             |
| sTREM-2         | 11441.0 [6009.0–20737.0]                                                          | 5254.0 [2384.0–8123.0]                                     |

BDL = below detection limit.
N/A = not available in the literature.
CI = confidence interval.
CSF of BoDV-1 patients from the two phases were compared with each other. Statistical analyses were performed with Mann-Whitney test, and no significant differences were detected between the phases.
No statistical analyses were performed between the two phases and the reference values from the literature.
The two immunosuppressed patients were not included in the statistical analysis.

Emerging Microbes & Infections
Figure 2. Cytokine, chemokine, growth factor and other biomarker changes in serum and cerebrospinal fluid of patients with BoDV-1 encephalitis in two phases of illness. Serum (black) and CSF (grey) samples from ten BoDV-1 encephalitis patients and serum samples from ten healthy controls (hc) were analyzed in parallel for cytokines (panel A), chemokines (panel B), growth factors (panel C) and other biomarkers (panel D) by bead-based LEGENDplex assay. Results of two immunosuppressed patients are highlighted, patient 4 in red and patient 5 in blue. See Table 2 for median measurements of patient biomarkers and healthy controls in serum (including p values and confidence intervals) and Table 3 for median measurements of patient biomarkers (including confidence intervals) and reference values of biomarkers in CSF. For analysis, sampling dates of the patients were assigned to different phases of the illness after symptom onset. Therefore, the individual duration of illness in each patient was split in two equally long time periods (halves). Data are shown as median with interquartile range. β-NGF, beta-nerve growth factor; BDNF, brain-derived neurotrophic factor; CCL, CC-chemokine ligand; CXCL, C-X-C motif chemokine; G-CSF, granulocyte colony-stimulating factor; IFN, interferon; IL, interleukin; PDGF-BB, platelet-derived growth factor BB; sRAGE, soluble receptor for advanced glycation end products; sTREM, soluble triggering receptor expressed on myeloid cells; TGF, transforming growth factor; VEGF, vascular endothelial growth factor; VILIP, visinin-like protein.
activated astrocytes, and in a few microglia (Figure 4(E)). TIMP1 was detected in activated astrocytes and in oligodendrocytes (Figure 4(F)). Control sections omitting the primary antibody did not show any specific staining (not shown).

**Discussion**

In this study, we demonstrate a marked immune activation in patients with severe and finally fatal BoDV-1 encephalitis. Our analysis using a broad range of flow cytometry-based biomarker detection assays, qRT-PCR-facilitated biomarker mRNA measurements and immunostaining show striking changes in serum, CSF, and brain tissue, respectively. Our investigation provides a glimpse on the rather complex changes of serum and CSF inflammatory changes during disease progression of fatal BoDV-1 encephalitis. The splitting in two phases of BoDV-1 encephalitis disease provided a more detailed insight into the immunopathology. In the BoDV-1 encephalitis patients, elevations of the pro-inflammatory cytokines IFNγ and IL-6 were shown, with a decrease of anti-inflammatory IL-13 and an upregulation of anti-inflammatory TGF-β1 levels. This mixed cytokine state is dominated by pro-inflammatory activation intensifying over time in phase 2 and partly counteracted by anti-inflammatory markers. This was paralleled by increased levels of various chemokines such as pro-inflammatory CCL-2 and CXCL-10 mainly in CSF of BoDV-1 patients, and most strikingly by the angiogenetic factor/neutrophil attractant IL-8, likely reflecting ongoing attraction of immune cells to the site of infection and further contributing to inflammation and tissue damage. Growth factor levels of BDNF, β-NGF, PDGF-BB were strikingly decreased in the patients. Only VEGF concentrations showed increases in CSF, likely reflecting tissue repair attempts in phase two of the disease. While the levels of the other biomarkers arginase and sTREM-2 increased from the first to the second phase of illness in serum, arginase levels in CSF remained within reference limits and sTREM-2 increased. Arginase induces polarization of microglia to an anti-inflammatory state and neuroprotection by reduction of nitric oxide (NO) production [34], whereas sTREM2s promote microglial survival and stimulate the production of inflammatory cytokines [32,33]. Thus, the levels of these other biomarkers also contributed to the pro-inflammatory state in the CNS toward phase two of BoDV-1 encephalitis. In the two immunosuppressed patients (patients 4 and 5), no specific pro-inflammatory or anti-inflammatory pattern could be seen that would stand out as specific for both of them, but both of them had the longest duration of disease. In patient 5, many cytokines and chemokines showed high elevations; this patient might have been an individual high cytokine responder as seen in other diseases. Unfortunately, no samples were available from the second phase of disease in either of these two patients to further evaluate and compare the findings of the first phase. Testing of serum and CSF during meningitis and encephalitis is an emerging field. Many chemokines and cytokines were found to be elevated during bacterial and viral CNS infections as shown by others [21]; thus, the changes seen in our investigation might not be specific for BoDV-1 encephalitis. Similar to other, non-specific forms of viral meningitis [21], we observed IFNγ and chemokine elevations in the CSF. As the current and severe BoDV-1 encephalitis was the most prominent condition in the patients, we strongly assume that the changes of biomarkers are associated with the current BoDV-1 disease. We cannot exclude, however, that any underlying disease might have influenced the mediator changes in addition.

In autopic brain tissue, representing the end of phase two of disease, only few biomarkers were detectable likely due to RNA degradation (see further below). Of those which could be successfully examined (GFAP, IFNγ, IL6, FGF1, TGFβ1 and TIMP1), especially IFNG and IL6 were upregulated when compared to healthy control brain tissue. These pro-inflammatory cytokines were also found to be upregulated in CSF during infection, and IL-6 also in serum. Immunostaining revealed IFNγ production in endothelial cells, microglia and astrocytes, while IL-6 production was shown in ramified activated microglia. In contrast, FGF1 mRNA levels were decreased when compared to healthy controls. This finding is in line with the decreased levels of most growth factors in serum and CSF during BoDV-1 encephalitis. Weak positivity was demonstrated in perivascular brain cells, oligodendrocytes and astrocytes by immunostaining. TGFβ1 was moderately upregulated in brain tissue during the final stage of the infection when compared to controls, likely mirroring the elevated serum concentration of anti-inflammatory TGF-β1. Unfortunately, no CSF reference values were available. Production of TGF-β1 was shown in endothelial cells, activated astrocytes and in a few microglia. TIMP1 levels in tissue were also only moderately elevated; production was demonstrated in oligodendrocytes and in activated and enlarged astrocytes. TIMP1 is secreted by astrocytes in the early phase of inflammation and a neuroprotective attempt [35]. In astrocytes, our investigation showed also increased GFAP production, a general immunostaining hallmark of activation [36,37]. Such activated, bizarre and enlarged astrocytes were demonstrated in both VSBV-1 [19] and BoDV-1 encephalitis [9,11]. No obvious correlations between the BoDV-1 copy numbers and gene expressions for GFAP, FGF1 and TGFβ1 were seen when both patients were compared. No correlations between viral copy numbers
and mediator gene expressions were found either when the different brain areas were compared within one patient. However, higher viral loads were detected in patient 3, who had a shorter course of disease than patient 11. Also in the related human VSVG encephalitis, higher viral loads were found to be associated with shorter disease duration and thus earlier death of the patients [19]. However, the relation of viral copy numbers to disease course and mediator gene expression is based on a few patients only and warrants further investigations.

Astrocytes account for roughly 30% of the cells in the CNS. Besides the long-known homeostatic functions of these cells (i.e. scar formation, repair of blood–brain-barrier, neurotrophic support, synaptic and extracellular fluid maintenance), there is mounting evidence for an important immunological role during inflammation which includes cytokine secretion [37–39]. Microglia represent 15% of the cells of the brain parenchyma, and, as macrophage-like cells of the CNS, are responsible for establishing innate immune responses to pathogens, clearance of pathogens and debris, and maintaining tissue homeostasis [40]. Differently activated microglia, such as pro-inflammatory M1 microglia and anti-inflammatory M2 microglia, induce at least two reactive astrocyte states during neuroinflammation (or vice versa) and form a functional axis [37,38,40,41]: A1 astrocytes are regarded as pro-inflammatory and neurotoxic, whereas A2 astrocytes are seen as anti-inflammatory and neurotrophic [35,37,38]. The concept has been adopted from the original M1/M2 macrophage paradigm which reflects immunoregulation outside the CNS. While the biomolecules C1q, C3, CCL-2, CCL-20, CCR-2, CXCL-10, IFNγ, IL-1α/β, IL-6, IL-12, IL-23, LCN2, NO/NOS2, TNF (not exhaustive) are A1/M1 activation markers, the biomolecules arginase, CCL-17, CCL-22, CCL-24, CXCL-4, FGF1, FIZZ1,

![Figure 3](imageURL)
IL-3, IL-4, IL-10, IL-21, IL-33, MRC1, RETNLB, TGF-β1, TIMP1, VEGF (not exhaustive) reflect an A2/M2 state [34, 37–41]. In our study, astrocytes showed production of pro-inflammatory IFNy and less so of anti-inflammatory TGF-β1, embedded in, and likely responsible for, a predominantly A1/M1 soluble cytokine milieu maintaining ongoing inflammation in the brain.

In animals, lesions in the CNS during natural Borna disease or experimental infection are caused by a T cell-mediated immunopathology [42,43]; symptoms begin with the appearance of CD4 and CD8 T cells.
in the brain. Although antiviral CD8 T cells recognize BoDV-1 antigen in neurons and astrocytes [44], the functional avidity of these cells is apparently down-modulated during BoDV-1 infection [45]. While cytotoxic CD8 T cells were experimentally shown to be induced by virus-specific CD4 T cells [46], the CD8 cells required IFNγ to clear the virus from the brain [47]. In our study IFNγ production was demonstrated in endothelial cells, astrocytes and microglia, and the biomarker was present in CSF. Likewise, in experimental rodent studies with BoDV-1, increased IFNγ mRNA concentrations were also seen [48,49]. In animals, BoDV-1 was shown to replicate initially in neurons and later in astrocytes [50]. In a recent study of human BoDV-1 pathology no virus RNA was seen in microglial cells [11]. In vitro experiments hint at an important role of astrocytes activating microglia during BoDV-1 infection which, in turn, produce IL-6 [51,52]. In our study, IL-6 production was also shown in microglia, as well as in serum and CSF. Similarly, increased IL-6 mRNA concentrations were seen in experimental rodent infections with BoDV-1 [48,49]. Besides such IFNγ and IL-6 pro-inflammatory cytokine responses in animals, which included also IL-1, IL-2 and TNF mRNA elevations, anti-inflammatory responses by IL-4 and TGF-β mRNA increases were seen [49]. In another rodent model, the administration of TGF-β led to a transient inhibition of symptomatic BoDV-1 disease, paralleled by a significant reduction of the inflammatory reaction in the brain with reduced CD4+ T cells and markedly decreased CD8+ cells [53]. While we did not detect IL-1, IL-2, TNF and IL-4 responses in our patient cohort, TGF-β1 responses were seen. In rodents, a shift from TH1 to TH2 cytokine responses was assumed based on IL-4 and TGF-β1 elevations during the course of experimental BoDV-1 infection which led from an acute encephalitis to a chronic persistent viral infection [49]. Such a shift from a corresponding A1/M1 to A2/M2 state in human BoDV-1 encephalitis was not that evident and only weak, and might therefore be a possible reason for the fatal outcomes of human infections.

Moreover, similar to the generally decreased growth factor levels described here in the BoDV-1 patients, decreased mRNA concentrations of BDNF were seen in experimental rodent infections with BoDV-1 [48]. Besides the predominantly pro-inflammatory cytokine and chemokine milieu described here in acute human BoDV-1 encephalitis contributing to an assumed neurodamaging state, the impairment of normal astrocyte function may lead to excitotoxicity in neurons due to glutamate excess [42] and subsequent neuronal lesions. However, the impact of such astrocytic dysregulation warrants further investigation.

This study has several limitations. Our work demonstrates the difficulty in obtaining high-quality RNA for biomarker analysis from FFPE tissues. This is most probably due to the severe inflammation and tissue damage seen in BoDV-1 encephalitis and the post mortem tissue autolysis before fixation, complicated by the fixation process itself. The post mortem interval before fixation seems to be a key factor [54,55]. When compared to neuronal and glia gene expression, the housekeeping genes used as reference for RNA normalization, as in our case, are less affected [55]. We have therefore screened the respective tissues for measurably expressed housekeeping genes before analyzing the biomarker genes. In addition to these detrimental natural effects, the formalin fixation leading to nucleic acid cross-links renders RNA less accessible for PCR analysis [28]. It is likely that such analyses from fixed biopsies (rather than from fixed autopsy material) or rapidly fresh-frozen autopsy material will be of better quality and thus higher validity in future studies. As a further limitation of the study, only few patients were included in the analysis and not all materials were available from all individuals. Future studies will have to address the described immunopathological findings with more patients included. For some biomarkers no reference values for CSF were available in the literature, as hardly healthy subjects undergo lumbar puncture. Nonetheless, we here demonstrate an emerging picture of marked immunoactivation leading to complex inflammation and a neurodamaging state.

In conclusion, our data, though fragmentary, demonstrate an increasing immune activation from the initial phase to the last phase of acute BoDV-1 encephalitis. A pro-inflammatory state as part of the immunomediated pathology, shown by elevated respective cytokines, chemokines and other biomarkers, dominates during the course of human BoDV-1 encephalitis. This dysbalanced, pro-inflammatory state leads to the severe and mostly fatal outcome of human BoDV-1 encephalitis, and might be a key target for possible treatment attempts with immunomodulating or immunosuppressive drugs in addition to antivirals.

**Acknowledgments**

This study was performed within the Zoonotic Bornavirus Consortium (ZooBoCo) funded by the German Federal Ministry of Education and Research (BMBF), grant number 01KI2005C to DT. ZooBoCo is a consortium in the Research Network Zoonotic Infectious Diseases. JFS is supported by the Joachim Herz Foundation, Hamburg as a member of the graduate school “Infection Biology of Tropical Pathogens” at the Bernhard Nocht Institute for Tropical Medicine. Additional financial support by the BMBF for the Bornavirus Focal Point Bavaria was granted to HHN (grant number 01KI2002).

**Disclosure statement**

No potential conflict of interest was reported by the author(s).
Funding
This work was supported by Bundesministerium für Bildung und Forschung [grant number 01KI2005C]; Joachim Herz Stiftung [grant number 3490169]; Bornavirus Focal Point Bavaria [grant number 01KI2002].

ORCID
Christiane Herden http://orcid.org/0000-0003-1858-2267
Dennis Rubbenstroth http://orcid.org/0000-0002-8209-6274

References
[1] Hoffmann B, Tappe D, Höper D, et al. A variegated squirrel bornavirus associated with fatal human encephalitis. N Engl J Med. 2015 Jul 9;373(2):154–162.
[2] Tappe D, Schlottau K, Cadar D, et al. Occupation-associated fatal limbic encephalitis caused by variegated squirrel bornavirus 1, Germany, 2013. Emerg Infect Dis. 2018 Jun;24(6):978–987.
[3] Tappe D, Frank C, Homeier-Bachmann T, et al. Analysis of exotic squirrel trade and detection of human infections with variegated squirrel bornavirus 1, Germany, 2005 to 2018. Euro Surveill. 2019 Feb;24(8).
[4] Cadar D, Allendorf V, Schulze V, et al. Introduction and spread of variegated squirrel bornavirus 1 (VSBV-1) between exotic squirrels and spill-over infections to humans in Germany. Emerg Microbes Infect. 2021 Dec;10(1):602–611.
[5] Cadar D, Schmidt-Chanasit J, Tappe D. Genomic and micro-evolutionary features of Mammalian 2 orthobornavirus (Variegated Squirrel Bornavirus 1, VSBV-1). Microorganisms. 2021 May 25;9(6):1141.
[6] Eisermann P, Rubbenstroth D, Cadar D, et al. Active case finding of current bornavirus infections in human encephalitis cases of unknown etiology, Germany, 2018-2020. Emerg Infect Dis. 2021 May;27(5):1371–1379.
[7] Schlottau K, Forth L, Angstwurm K, et al. Fatal encephalitis due to the previously known area for human cases, Brandenburg, Germany – a case report. BMC Infect Dis. 2021 Aug 10;21(1):787.
[8] Nüller HH, Angstwurm K, Rubbenstroth D, et al. Zoonotic spillover infections with Bornavirus disease virus 1 leading to fatal human encephalitis, 1999-2019: an epidemiological investigation. Lancet Infect Dis. 2020 Apr;20(4):467–477.
[9] Korn K, Coras R, Bobinger T, et al. Fatal encephalitis associated with Bornavirus disease virus 1. N Engl J Med. 2018 Oct 4;379(14):1377–1379.
[10] Coras R, Korn K, Kuerten S, et al. Severe bornavirus-encephalitis presenting as Guillain-Barré-syndrome. Acta Neuropathol. 2019 Jun;137(6):1017–1019.
[11] Liesche F, Ruf V, Zoubaa S, et al. The neuropathology of fatal encephalomyelitis in human Bornavirus virus infection. Acta Neuropathol. 2019 Oct;138(4):653–665.
[12] Tappe D, Pörtner K, Frank C, et al. Investigation of fatal human Bornavirus disease virus 1 encephalitis outside the previously known area for human cases, Brandenburg, Germany – a case report. BMC Infect Dis. 2021 Aug 10;21(1):787.
[13] Frank C, Wickel J, Brämer D, et al. Human Bornavirus disease virus 1 (BoDV-1) encephalitis cases in the north and east of Germany. Emerg Microbes Infect. 2022 Dec;11(1):6–13.
[14] Neumann B, Angstwurm K, Linker RA, et al. Antibodies against viral nucleo-, phospho-, and X protein contribute to serological diagnosis of fatal Bornavirus disease virus 1 infections. Cell Rep Med. 2022 Jan 18;3(1):100499.
[15] Dürwald R, Kolodziejek J, Weissenböck H, et al. The bicolored white-toothed shrew Crocidura leucodon (HERMANN 1780) is an indigenous host of mammalian Bornavirus disease virus. PLoS One. 2014 Apr 3;9(4):e93659.
[16] Weissenböck H, Bagó Z, Kolodziejek J, et al. Infections of horses and shrews with Bornaviruses in upper Austria: a novel endemic area of Borna disease. Emerg Microbes Infect. 2017 Jun 21;6(6):e52.
[17] Nobach D, Bourg M, Herzog S, et al. Shedding of Infectious Borna disease virus-1 in living bicolored white-toothed shrews. PLoS One. 2015 Aug 27;10(8):e0137018.
[18] Tappe D, Frank C, Offergeld R, et al. Low prevalence of Bornavirus disease virus 1 (BoDV-1) IgG antibodies in humans from areas endemic for animal Borna disease of southern Germany. Sci Rep. 2019 Dec 27;9(1):20154.
[19] Tappe D, Schmidt-Chanasit J, Rauch J, et al. Immunopathology of fatal human Variegated Squirrel Bornavirus 1 encephalitis, Germany, 2011-2013. Emerg Infect Dis. 2019 Jun;25(6):1058–1065.
[20] Finck T, Liesche-Starnecker F, Probst M, et al. Bornavirus-Encephalitis Study Group. Bornavirus encephalitis shows a characteristic magnetic resonance appearance phenotype in humans. Ann Neurol. 2020 Oct;88(4):723–735.
[21] Lepennetier G, Hracako Z, Unger M, et al. Cytokine and immune cell profiling in the cerebrospinal fluid of patients with neuro-inflammatory diseases. J Neuroinflammation. 2019 Nov 14;16(1):219.
[22] Sun XG, Ma Q, Jing G, et al. Increased levels of soluble triggering receptor expressed on myeloid cells-1 in cerebrospinal fluid of subarachnoid hemorrhage patients. J Clin Neurosci. 2017 Jan;35:139–143.
[23] Lepej SZ, Misic-Majerus I, Jeren T, et al. Chemokines CXCL10 and CXCL11 in the cerebrospinal fluid of patients with tick-borne encephalitis. Acta Neurol Scand. 2007 Feb;115(2):109–114.
[24] Huang Y, Wang J, Zhu B, et al. CSF VEGF was positively associated with neurogranin independent of beta-amyloid pathology. Neuropsychiatr Dis Treat. 2020 Jul 22;16:1737–1744.
[25] Ou ZA, Byrne LM, Rodrigues FB, et al. Brain-derived neurotrophic factor in cerebrospinal fluid and plasma is not a biomarker for Huntington’s disease. Sci Rep. 2021 Feb 10;11(1):3481.
[26] Zimmermann J, Weller J, Grub S, et al. Arginase-1 released into CSF after aneurysmal subarachnoid hemorrhage decreases arginine/ornithine ratio: a novel prognostic biomarker. Transl Stroke Res. 2021 Oct 2;13(3):382–390.
[27] Laske C, Stranksy E, Leyhe T, et al. BDNF serum and CSF concentrations in Alzheimer’s disease, normal pressure hydrocephalus and healthy controls. J Psychiatr Res. 2007 Aug;41(5):387–394.
[28] Boos GS, Nobach D, Failing K, et al. Optimization of RNA extraction protocol for long-term archived formalin-fixed paraffin-embedded tissues of horses. Exp Mol Pathol. 2019 Oct;108:Article 104289.
[29] Pfaff MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001 May 1;29(9):e45.
[30] Caracausi M, Piovesan A, Antonaros F, et al. Systematic identification of human housekeeping genes possibly useful as references in gene expression studies. Mol Med Rep. 2017 Sep;16(3):2397–2410.

[31] Andersen CL, Jensen JL, Ørntoft TF. Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets. Cancer Res. 2004 Aug 1;64(15):5245–5250.

[32] Zhong L, Chen XF, Wang T, et al. Soluble TREM2 induces inflammatory responses and enhances microglial survival. J Exp Med. 2017 Mar 6;214(3):597–607.

[33] Groblewska M, Muszyński P, Wojtulewska-Supron A, et al. The role of visinin-like protein-1 in the pathophysiology of Alzheimer’s disease. J Alzheimers Dis. 2015;47(1):17–32.

[34] Tang Y, Le W. Differential roles of M1 and M2 microglia in neurodegenerative diseases. Mol Neurobiol. 2016 Mar;53(2):1181–1194.

[35] Saha P, Sarkar S, Paidi RK, et al. TIMP-1: A key cytokine released from activated astrocytes protects neurons and ameliorates cognitive behaviours in a rodent model of Alzheimer’s disease. Brain Behav Immun. 2020 Jul;87:804–819.

[36] Jang E, Kim JH, Lee S, et al. Phenotypic polarization of activated astrocytes: the critical role of lipocalin-2 in the classical inflammatory activation of astrocytes. J Immunol. 2013 Nov 15;191(10):5204–5219.

[37] Liddelow SA, Barres BA. Reactive astrocytes: production, function, and therapeutic potential. Immunity. 2017 Jun 20;46(6):957–967.

[38] Liddelow SA, Guttenplan KA, Clarke LE, et al. Neurotoxic reactive astrocytes are induced by activated microglia. Nature. 2017 Jan 26;541(7638):481–487.

[39] Roybon L, Lamas NJ, Garcia AD, et al. Human stem cell-derived spinal cord astrocytes with defined mature or reactive phenotypes. Cell Rep. 2013 Sep 12;4(5):1035–1048.

[40] Orihuela R, McPherson CA, Harry GJ. Microglial M1/M2 polarization and metabolic states. Br J Pharmacol. 2016 Feb;173(4):649–665.

[41] Cherry JD, Olschowka JA, O’Banion MK. Neuroinflammation and M2 microglia: the good, the bad, and the inflamed. J Neuroinflammation. 2014 Jun 3;11:98.

[42] Tizard I, Ball J, Stoica G, et al. The pathogenesis of bornaviral diseases in mammals. Anim Health Res Rev. 2016 Dec;17(2):92–109.

[43] Rott R, Herzog S, Richt J, et al. Immune-mediated pathogenesis of Borna disease. Zentralbl Bakteriol Mikrobiol Hyg A. 1988 Nov;270(1–2):295–301.

[44] Baur K, Rauer M, Richter K, et al. Antiviral CD8 T cells recognize borna disease virus antigen transgenically expressed in either neurons or astrocytes. J Virol. 2008 Mar;82(6):3099–3108.

[45] Engelhardt KR, Richter K, Baur K, et al. The functional avidity of virus-specific CD8+ T cells is down-modulated in Borna disease virus-induced immunopathology of the central nervous system. Eur J Immunol. 2005 Feb;35(2):487–497.

[46] Nööke K, Bilzer T, Planz O, et al. Virus-specific CD4+ T cells eliminate borna disease virus from the brain via induction of cytotoxic CD8+ T cells. J Virol. 1998 May;72(5):4387–4395.

[47] Hausmann J, Pagenstecher A, Baur K, et al. CD8 T cells require gamma interferon to clear borna disease virus from the brain and prevent immune system-mediated neuronal damage. J Virol. 2005 Nov;79(21):13509–13518.

[48] Briese T, Hornig M, Lipkin WI. Bornavirus immunopathogenesis in rodents: models for human neurological diseases. J Neurovirol. 1999 Dec;5(6):604–612.

[49] Hatalski CG, Hickey WF, Lipkin WI. Evolution of the immune response in the central nervous system following infection with Borna disease virus. J Neuroimmunol. 1998 Oct 1;90(2):137–142.

[50] Gosztonyi G, Ludwig H. Borna disease–neuropathology and pathogenesis. Curr Top Microbiol Immunol. 1995;190:39–73.

[51] Ovanesov MV, Sauder C, Rubin SA, et al. Activation of microglia by borna disease virus infection: in vitro study. J Virol. 2006 Dec;80(24):12141–12148.

[52] Ovanesov MV, Ayhan Y, Wolbert C, et al. Astrocytes play a key role in activation of microglia by persistent Borna disease virus infection. J Neuroinflammation. 2008 Nov 11:5:50.

[53] Stitz L, Planz O, Bilzer T, et al. Transforming growth factor-beta modulates T cell-mediated encephalitis caused by Borna disease virus. Pathogenic importance of CD8+ cells and suppression of antibody formation. J Immunol. 1991 Nov 15;147(10):3581–3586.

[54] Zhu Y, Wang L, Yin Y, et al. Systematic analysis of gene expression patterns associated with postmortem interval in human tissues. Sci Rep. 2017 Jul 14;7(1):5435.

[55] Dachet F, Brown JB, Valyi-Nagy T, et al. Selective time-dependent changes in activity and cell-specific gene expression in human postmortem brain. Sci Rep. 2021 Mar 23;11(1):6078.